Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TNXP

STRONG SELL

Tonix Pharmaceuticals Holding Corp. · Healthcare · United States · $157M · Avg Vol: $6M/d

12
StockRank
Get insider-trade alerts
Q
30
V
35
M
25
P/E (TTM)
—
ROE
-72.3%
D/E
0.0x
Dividend %
—
Dir. Trades · 180d
+$418.6K →
Buybacks · 180d
$10.9M →

COMPANY DESCRIPTION

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics and biologics to treat central nervous system disorders, immunology, and infectious diseases. The company's primary asset is Tonmya, a late-stage candidate for the management of fibromyalgia. Tonix operates as a high-risk, development-stage biotech player with a diversified pipeline, relying on clinical trial milestones and capital markets to fund its path to commercialization.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue07.8M10.1M13.1M29.9%17.6M34.2M78.9M145.4%
EPS-15.68-16.91-48.59-14.57—-12.96-10.10-7.80—
Shares15.9M15.9M15.9M12.8M-19.8%15.9M———
Debt0.8M9.8M8.1M1.3M19.9%1.3M———
Equity207.2M105.5M139.6M245.2M5.8%————
Op CF-98.1M-102.0M-60.9M-99.8M—-125.6M———
Inv CF-48.1M-29.1M-0.1M-4.5M—————
Fin CF87.8M36.5M134.9M214.5M—————
Loading 1Y...
PRICE (1Y)-8.6%
9.8810.7211.5512.3913.22Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$10.37
RSI (14)
35.2
52W High
$69.97
From 52W High
0.1%

SCORE BREAKDOWN

Quality
30
ROIC
-50.3%15.2
ROE
-72.3%12.7
GP/Assets
3.7%17.6
Op. Margin
-603.9%9.7
FCF/Assets
-27.7%12.9
Piotroski
668.3
Int. Cover
-50.0x6.3
D/E Ratio
0.01x87.8
Current Ratio
6.99x79.8
Value
35
P/E (TTM)
—N/A
EV/EBITDA
0.1x25.0
P/FCF
—N/A
P/B
0.7x92.7
P/S
10.0x27.1
Div Yield
—N/A
Momentum
25
52W High %
15%1.9
RS 6M
-51%13.8
SMA 50/200
0.81x20.7
EPS Rev 4W
0.0%62.6
EPS Rev 12W
—N/A
EPS Improve
+40%50.1
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$157M
P/E (Forward)
-1.4x
Gross Margin
58.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNXP are excluded.

TickerCompanyMkt CapStockRankSignal
TNXPTonix Pharmaceuticals Holding Corp.(you)$157M12STRONG SELL
KRROKorro Bio, Inc.$153M12STRONG SELL
UNCYUnicycive Therapeutics, Inc.$148M14STRONG SELL
ARCTArcturus Therapeutics Holdings Inc.$157M15STRONG SELL
PYXSPyxis Oncology, Inc.$165M14STRONG SELL
CAMPCAMP4 THERAPEUTICS CORPORATION$164M10STRONG SELL
ABOSAcumen Pharmaceuticals, Inc.$154M15STRONG SELL
0HIY.LAtara Biotherapeutics, Inc.$161M10STRONG SELL
IVVDInvivyd, Inc.$180M12STRONG SELL
CBUSCibus, Inc.$138M12STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%

Tonix Pharmaceuticals Holding Corp. (TNXP) — Stock Score Summary

Tonix Pharmaceuticals Holding Corp. (TNXP) has a MoatMap StockRank of 12/100 based on Quality (30/100), Value (35/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics and biologics to treat central nervous system disorders, immunology, and infectious diseases. The company's primary asset is Tonmya, a late-stage candidate for the management of fibromyalgia. Tonix operates as a high-risk, development-stage biotech player with a diversified pipeline, relying on clinical trial milestones and capital markets to fund its path to commercialization.

Key Financial Metrics

Price$10.37
Market Cap$157M
P/E (Forward)-1.41
Price/Book0.69
Return on Equity-72.3%
Return on Invested Capital-50.3%
Debt/Equity0.01x
Gross Margin58.6%
Operating Margin-603.9%
Revenue Growth183.2%
Free Cash Flow$-77M

Tonix Pharmaceuticals Holding Corp. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Tonix Pharmaceuticals Holding Corp.’s (TNXP) StockRank?
MoatMap’s StockRank for Tonix Pharmaceuticals Holding Corp. (TNXP) is 12/100, with a Strong Sell signal. It is a composite of Quality (30), Value (35), and Momentum (25) factor ranks across MoatMap’s 20,000+ stock universe.
Does Tonix Pharmaceuticals Holding Corp. have an economic moat?
Tonix Pharmaceuticals Holding Corp. (TNXP) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tonix Pharmaceuticals Holding Corp. a buy, hold, or sell?
MoatMap’s current signal for Tonix Pharmaceuticals Holding Corp. (TNXP) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tonix Pharmaceuticals Holding Corp. in?
Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksTNXP deep dive reportAI ChampionsHow we score stocksSense-check another stock